Literature DB >> 20500683

Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects.

L-Z Sun1, S Elsayed, T B Aasen, T Van Do, N P Aardal, E Florvaag, K Vaali.   

Abstract

Ovalbumin (OVA) is widely used in allergy research. OVA peptide 323-339 has been reported to be responsible for 25-35% of isolated BALB/c mouse T-cell response to intact OVA. An investigation of whether OVA and OVA 323-339 molecules can induce equivalent in vivo and in vitro immune responses was conducted. Eight-week-old BALB/c mice were randomly divided into three groups: OVA, OVA 323-339 and saline. On days 0, 7, 14, mice were intraperitoneally injected with 25 microg OVA or OVA 323-339 absorbed on 300 microg Alum, or saline; on days 21-23, all groups were challenged intranasally with either 20 microl of 1% OVA, 1% OVA 323-339 or saline. On day 28, after killing, splenocytes were isolated and cultured under the stimulus of each allergen or medium. Evaluated by hematoxylin/eosin and major basic protein immunohistochemical stainings, OVA and OVA 323-339 induced similar lung inflammation. Interestingly, significant serum total IgE and OVA-specific IgE were observed in OVA mice when compared to saline control. OVA 323-339 mice showed higher serum OVA-specific IgE, OVA 323-339-specific IgE, IL-4 and lower IFN-gamma similar to OVA mice. The proliferative response to OVA was found in cultured splenocytes of both OVA and OVA 323-339 mice, while the similar proliferative response to OVA 323-339 was only observed in the splenocytes of OVA 323-339-sensitized and challenged mice. Although OVA 323-339 induced a Th2-like response in the mouse model as did OVA, OVA 323-339 has clearly limited immunogenic potency to activate OVA-sensitized and challenged mice splenocytes, unlike OVA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500683     DOI: 10.1111/j.1365-3083.2010.02382.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Design, synthesis and characterisation of mannosylated ovalbumin lipid core peptide self-adjuvanting vaccine delivery system.

Authors:  Pavla Simerska; Zyta Maria Ziora; Vincent Fagan; Daryn Goodwin; Farrah Edrous; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

2.  Intratracheal exposure to Fab fragments of an allergen-specific monoclonal antibody regulates asthmatic responses in mice.

Authors:  Shin Yoshino; Nobuaki Mizutani; Daiko Matsuoka; Chutha Sae-Wong
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

3.  A Modular Vaccine Platform Combining Self-Assembled Peptide Cages and Immunogenic Peptides.

Authors:  Caroline Morris; Sarah J Glennie; Hon S Lam; Holly E Baum; Dhinushi Kandage; Neil A Williams; David J Morgan; Derek N Woolfson; Andrew D Davidson
Journal:  Adv Funct Mater       Date:  2019-01-11       Impact factor: 18.808

4.  Tyrosol improves ovalbumin (OVA)-induced asthma in rat model through prevention of airway inflammation.

Authors:  Mustafa Cellat; Müslüm Kuzu; Cafer Tayer İşler; Muhammed Etyemez; Nursel Dikmen; Ahmet Uyar; İshak Gökçek; Erdinç Türk; Mehmet Güvenç
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-21       Impact factor: 3.000

5.  Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice.

Authors:  Krisztina Manzano-Szalai; Kathrin Thell; Anna Willensdorfer; Margit Weghofer; Beatrix Pfanzagl; Josef Singer; Mirko Ritter; Caroline Stremnitzer; Ingo Flaschberger; Uwe Michaelis; Erika Jensen-Jarolim
Journal:  Viral Immunol       Date:  2014-09-23       Impact factor: 2.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.